Compare CVE & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVE | TAK |
|---|---|---|
| Founded | 2009 | 1781 |
| Country | Canada | Japan |
| Employees | 8300 | 47455 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0B | 52.4B |
| IPO Year | N/A | N/A |
| Metric | CVE | TAK |
|---|---|---|
| Price | $24.69 | $15.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $30.50 | N/A |
| AVG Volume (30 Days) | ★ 8.3M | 2.9M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | 2.03% | ★ 3.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $0.16 |
| Revenue Next Year | $2.74 | $1.22 |
| P/E Ratio | ★ $18.07 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.47 | $12.99 |
| 52 Week High | $32.07 | $18.90 |
| Indicator | CVE | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 33.72 | 49.94 |
| Support Level | $24.22 | $15.88 |
| Resistance Level | $30.47 | $16.03 |
| Average True Range (ATR) | 0.76 | 0.21 |
| MACD | -0.35 | 0.07 |
| Stochastic Oscillator | 8.45 | 78.99 |
Cenovus Energy Inc is a Canadian integrated energy group. The group's upstream operations include oil sands projects in northern Alberta; thermal and conventional crude oil, natural gas, and natural gas liquids (NGLs) projects across Western Canada; crude oil production offshore Newfoundland and Labrador; and natural gas and NGLs production offshore China and Indonesia. Its downstream operations include upgrading and refining operations in Canada and the U.S., and commercial fuel operations across Canada. The group's reportable segments are: Oil Sands, Conventional, Offshore, Canadian Refining, U.S Refining, and Corporate and Eliminations. Maximum revenue is generated from its Oil Sands segment. Geographically, the group derives maximum revenue from the U.S., followed by Canada and China.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.